Light-Activated Liposomes Coated with Hyaluronic Acid as a Potential Drug Delivery System.
biocorona
drug release
hyaluronic acid
light activation
liposome
mobility
stability
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
12 Aug 2020
12 Aug 2020
Historique:
received:
06
07
2020
revised:
05
08
2020
accepted:
09
08
2020
entrez:
19
8
2020
pubmed:
19
8
2020
medline:
19
8
2020
Statut:
epublish
Résumé
Light-activated liposomes permit site and time-specific drug delivery to ocular and systemic targets. We combined a light activation technology based on indocyanine green with a hyaluronic acid (HA) coating by synthesizing HA-lipid conjugates. HA is an endogenous vitreal polysaccharide and a potential targeting moiety to cluster of differentiation 44 (CD44)-expressing cells. Light-activated drug release from 100 nm HA-coated liposomes was functional in buffer, plasma, and vitreous samples. The HA-coating improved stability in plasma compared to polyethylene glycol (PEG)-coated liposomes. Liposomal protein coronas on HA- and PEG-coated liposomes after dynamic exposure to undiluted human plasma and porcine vitreous samples were hydrophilic and negatively charged, thicker in plasma (~5 nm hard, ~10 nm soft coronas) than in vitreous (~2 nm hard, ~3 nm soft coronas) samples. Their compositions were dependent on liposome formulation and surface charge in plasma but not in vitreous samples. Compared to the PEG coating, the HA-coated liposomes bound more proteins in vitreous samples and enriched proteins related to collagen interactions, possibly explaining their slightly reduced vitreal mobility. The properties of the most abundant proteins did not correlate with liposome size or charge, but included proteins with surfactant and immune system functions in plasma and vitreous samples. The HA-coated light-activated liposomes are a functional and promising alternative for intravenous and ocular drug delivery.
Identifiants
pubmed: 32806740
pii: pharmaceutics12080763
doi: 10.3390/pharmaceutics12080763
pmc: PMC7465487
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Academy of Finland
ID : 311122
Organisme : Academy of Finland
ID : 317336
Organisme : Business Finland
ID : 4208/31/2015
Organisme : Horizon 2020
ID : 676137
Organisme : Orionin Tutkimussäätiö
ID : 9-8214-9
Organisme : Phospholipid Research Center
ID : 0
Organisme : Emil Aaltosen Säätiö
ID : 0
Organisme : Instrumentariumin Tiedesäätiö
ID : 0
Organisme : Mary och Georg C. Ehrnrooths Stiftelse
ID : 0
Organisme : Evald ja Hilda Nissin Säätiö
ID : 0
Organisme : Inkeri and Mauri Vänskä Foundation
ID : 0
Organisme : Paulon Säätiö
ID : 0
Organisme : Päivikki ja Sakari Sohlbergin Säätiö
ID : 0
Références
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):655-77
pubmed: 25707913
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Mar-Apr;4(2):219-33
pubmed: 22231928
Chem Soc Rev. 2012 Apr 7;41(7):2780-99
pubmed: 22086677
Nanoscale. 2020 Jan 23;12(3):1728-1741
pubmed: 31894806
Biochim Biophys Acta. 2003 May 2;1612(1):76-82
pubmed: 12729932
Nat Nanotechnol. 2012 Dec;7(12):779-86
pubmed: 23212421
Nanomedicine. 2013 Jan;9(1):1-14
pubmed: 22684017
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Int J Pharm. 2007 Mar 1;331(2):186-9
pubmed: 17145145
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Cell Mol Biol Lett. 2005;10(1):37-47
pubmed: 15809678
Nat Nanotechnol. 2013 Oct;8(10):772-81
pubmed: 24056901
Cell. 2012 Aug 31;150(5):1068-81
pubmed: 22939629
Drug Discov Today. 2017 Apr;22(4):665-680
pubmed: 28017836
J Biomed Mater Res A. 2006 Sep 1;78(3):620-8
pubmed: 16779767
Photochem Photobiol. 2009 Jul-Aug;85(4):848-60
pubmed: 19222790
NanoImpact. 2016 Apr;2:38-44
pubmed: 29202111
ACS Nano. 2015 Dec 22;9(12):11872-85
pubmed: 26575243
Sci Rep. 2016 Nov 21;6:36928
pubmed: 27869206
PLoS One. 2015 May 28;10(5):e0127567
pubmed: 26020955
Acta Biomater. 2018 Apr 15;71:420-431
pubmed: 29524674
Acta Biomater. 2014 Oct;10(10):4351-9
pubmed: 24932771
ACS Nano. 2015 Aug 25;9(8):8142-56
pubmed: 26135229
J Control Release. 2013 Apr 10;167(1):76-84
pubmed: 23369761
PLoS One. 2013 Sep 09;8(9):e74001
pubmed: 24040142
Cancer Res. 2001 Mar 15;61(6):2592-601
pubmed: 11289136
Biomaterials. 2016 Dec;109:23-31
pubmed: 27648757
J Control Release. 2018 Aug 28;284:213-223
pubmed: 29964133
Biomaterials. 2011 Mar;32(7):1880-9
pubmed: 21159377
Prog Retin Eye Res. 2000 May;19(3):323-44
pubmed: 10749380
Mol Pharm. 2016 Sep 6;13(9):2977-86
pubmed: 26741026
Nanoscale. 2018 Jun 14;10(22):10731-10739
pubmed: 29845991
Eur J Pharm Sci. 2017 May 30;103:128-135
pubmed: 28285174
Trends Biotechnol. 2018 Aug;36(8):755-769
pubmed: 29559165
J Control Release. 2016 Dec 28;244(Pt B):157-166
pubmed: 27565215
Biomaterials. 2004 Jul;25(16):3259-66
pubmed: 14980420
J Biomed Mater Res A. 2008 Dec 1;87(3):656-65
pubmed: 18189301
J Pharm Sci. 2003 Oct;92(10):2090-7
pubmed: 14502548
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Biochemistry. 2014 Mar 4;53(8):1275-83
pubmed: 24512123
J Control Release. 2018 Apr 28;276:157-167
pubmed: 29522832
Nat Commun. 2017 Oct 3;8(1):777
pubmed: 28974673
Langmuir. 2016 May 10;32(18):4554-63
pubmed: 27089512
Biophys J. 2015 Nov 17;109(10):2171-81
pubmed: 26588575
ACS Nano. 2017 Dec 26;11(12):11773-11776
pubmed: 29206030
Nat Biotechnol. 2007 Oct;25(10):1165-70
pubmed: 17891134
Nat Nanotechnol. 2015 May;10(5):472-9
pubmed: 25822932
Mol Pharm. 2020 Jul 8;:
pubmed: 32584047
Mol Pharm. 2016 Jun 6;13(6):1800-8
pubmed: 27112287
Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308
pubmed: 20648499
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947
Int J Mol Sci. 2014 Dec 12;15(12):23090-140
pubmed: 25514413
Mol Pharm. 2016 Jun 6;13(6):2095-107
pubmed: 27097108
Nat Rev Drug Discov. 2005 Feb;4(2):145-60
pubmed: 15688077